Antibodies against human CSF-1R
The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
1. An isolated antibody binding to human macrophage colony-stimulating factor 1 receptor (CSF-1R), or an antibody fragment thereof, wherein the antibody comprises
a heavy chain variable domain comprising a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6.
2. The antibody, or antibody fragment thereof, of claim 1 , wherein the antibody comprises
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8.
3. The antibody, or antibody fragment thereof, of claim 1 , wherein the antibody is a human IgG4 subclass or a human IgG1 subclass antibody, or antibody fragment thereof.
4. A pharmaceutical composition comprising the antibody, or antibody fragment thereof, of claim 1 .
5. The pharmaceutical composition of claim 4 , further comprising a pharmaceutically acceptable carrier.
6. The antibody, or antibody fragment thereof, of claim 1 , wherein the antibody is a CDR grafted, humanized, T cell epitope depleted, chimeric, single chain, or multispecific antibody.
7. An antibody binding to human CSF-1R, or an antibody fragment thereof, obtained from or produced by hybridoma cell line <CSF-1R>7G5.3B6.
8. The antibody, or antibody fragment thereof, of claim 1 or 7 , wherein the antibody is capable of binding human CSF-1R with a Kd value of 1 nM or lower.
9. The antibody, or antibody fragment thereof, of claim 1 or 7 , wherein the antibody inhibits human CSF-1 binding to CSF-1R with an IC50 value of 25 ng/ml or lower.
10. The antibody, or antibody fragment thereof, of claim 1 or 7 , wherein the antibody is a monoclonal antibody.
11. An immunoconjugate comprising the antibody of claim 1 or 7 and a cytotoxic agent.
12. The immunoconjugate of claim 11 , wherein the cytotoxic agent is a chemotherapeutic agent, a growth inhibitory agent, a toxin, or a radioactive isotope.